Analysts Set Danaher Corporation (NYSE:DHR) Target Price at $228.91

Danaher Corporation (NYSE:DHR) has been assigned a consensus rating of “Moderate Buy” from the twenty-five research firms that are currently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation, nineteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $228.9130.

A number of equities research analysts have issued reports on DHR shares. Wells Fargo & Company cut their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. DZ Bank started coverage on shares of Danaher in a research report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 target price for the company. Stifel Nicolaus cut their target price on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Finally, Royal Bank Of Canada boosted their price target on shares of Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 22nd.

Danaher Stock Up 0.2%

Shares of DHR stock opened at $215.74 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher has a 12 month low of $160.93 and a 12 month high of $242.80. The stock has a market cap of $151.67 billion, a P/E ratio of 38.32, a P/E/G ratio of 2.68 and a beta of 0.78. The company has a 50 day simple moving average of $198.69 and a two-hundred day simple moving average of $192.35.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the company earned $0.77 earnings per share. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. On average, research analysts expect that Danaher will post 8.53 earnings per share for the current year.

Institutional Trading of Danaher

Large investors have recently made changes to their positions in the business. EP Wealth Advisors LLC purchased a new position in shares of Danaher in the 2nd quarter valued at approximately $3,807,000. Northwestern Mutual Wealth Management Co. increased its stake in Danaher by 303.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after purchasing an additional 186,584 shares in the last quarter. Puzo Michael J acquired a new position in Danaher during the 2nd quarter valued at approximately $8,624,000. Madison Asset Management LLC purchased a new position in shares of Danaher in the second quarter worth $85,451,000. Finally, Legal & General Group Plc lifted its stake in shares of Danaher by 1.0% during the fourth quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock worth $1,029,061,000 after buying an additional 43,169 shares during the period. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.